Tom,
Are you referring to the PR on Sept. 27th regarding the formation of MaxPharma....?
Do you think the U of M is one of those focused "third parties with the view to their eventual involvement in the financing and future success of MaxPharma"? or Dr. Azzazy or MIPS or ALL of them? Hmmmmm, perhaps the FINDINGS will entice o t h e r "third parties"....
prnewswire.com
CEL-SCI Corporation Forms New Company
VIENNA, Va., Sept. 27 /PRNewswire/ -- CEL-SCI Corporation
(Amex: HIV; Berlin Stock Exchange: LSR) announces that it has formed a
separate entity, called MaxPharma, to develop its L.E.A.P.S.(TM) technology.
This new structure allows the Company's management to concentrate more on its
leading developmental product, Multikine(TM), which is currently being
evaluated in human clinical trials in six countries.
L.E.A.P.S. activates the immune system in specific and potent ways to
fight cancer, infectious diseases and autoimmune diseases. The technology has
three unique characteristics: 1) strong, specific activation of the T-cell
response, as shown in animal models; 2) fast and efficient integration of
selected epitopes (specific immune "triggers") from a variety of sources; and,
3) ability to facilitate disease antigen presentation and to direct immune
response outcome, a major breakthrough. The L.E.A.P.S. technology is patent
protected in key markets.
Geert Kersten, Chief Executive Officer of CEL-SCI, said, "We believe that
both L.E.A.P.S. and Multikine will benefit from this dedicated focus and that
this transaction will ultimately increase shareholder value."
As part of the creation of MaxPharma, the Company is in discussion with a
variety of third parties with the view to their eventual involvement in the
financing and future success of MaxPharma. CEL-SCI intends to retain a
significant share in MaxPharma's equity. The precise structure of MaxPharma
will be decided upon consultation with the outside investor(s).
The creation of MaxPharma enables CEL-SCI to focus both management time,
as well as its financial resources, on the future development of Multikine.
Multikine's most extensive current development covers its evaluation as a pre-
surgical regimen in patients with head and neck cancer.
CEL-SCI Corporation is a biopharmaceutical company whose mission it is to
use the immune system to combat disease.
"CEL-SCI press releases are available through Company News On-Call by fax,
800-758-5804, Ext. 445563, or at cel-sci.com on the Internet."
When used in this report, the words "intends," "believes," "anticipated"
and "expects" and similar expressions are intended to identify forward-looking
statements. Such statements are subject to risks and uncertainties which
could cause actual results to differ materially from those projected. Factors
that could cause or contribute to such differences include, an inability to
duplicate the clinic results demonstrated in preclinical studies, timely
development of any potential products that can be shown to be safe and
effective, receiving necessary regulatory approvals, difficulties in
manufacturing any of the Company's potential products and the risk factors set
forth from time to time in CEL-SCI Corporation's SEC filings, including but
not limited to its report on Form 10-K for the year ended September 30, 1998.
The Company undertakes no obligation to publicly release the result of any
revision to these forward-looking statements which may be made to reflect the
events or circumstances after the date hereof or to reflect the occurrence of
unanticipated events
SOURCE CEL-SCI Corporation
Web Site: cel-sci.com
------------------------------------------------------------------------
------------------------------------------------------------------------
¸1996-1999 PR Newswire. All rights reserved.
Redistribution, retransmission, republication or commercial exploitation of the contents of this site are expressly prohibited without the written consent of PR Newswire.
These pages have been optimized for Netscape v.2.0 or later |
